(Q41195126)

28 September 2017

1 reference

title

Clinical studies with solvent detergent-treated products (English)

1 reference

28 September 2017

Pehta JC

1

1 reference

28 September 2017

1 October 1996

1 reference

Transfusion Medicine Reviews

28 September 2017

1 reference

28 September 2017

10

1 reference

28 September 2017

303-311

1 reference

28 September 2017

4

1 reference

Inactivation of hepatitis B and Hutchinson strain non-A, non-B hepatitis viruses by exposure to Tween 80 and ether.

28 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980006-X

7 January 2021

Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate.

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980006-X

7 January 2021

Tri(n-butyl) phosphate/detergent treatment of licensed therapeutic and experimental blood derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980006-X

7 January 2021

The use of tri(n-butyl)phosphate detergent mixtures to inactivate hepatitis viruses and human immunodeficiency virus in plasma and plasma's subsequent fractionation

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980006-X

7 January 2021

Virus safety of solvent/detergent-treated antihaemophilic factor concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980006-X

7 January 2021

Low risk of transmission of the human immunodeficiency virus by a solvent-detergent-treated commercial factor VIII concentrate

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980006-X

7 January 2021

In vitro and in vivo evaluation of two factor VIII concentrates virally inactivated by solvent-detergent or by pasteurization

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980006-X

7 January 2021

Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980006-X

7 January 2021

Virology of the hepatitis A epidemic in Italy

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980006-X

7 January 2021

Review of the hepatitis A epidemics in hemophiliacs in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980006-X

7 January 2021

Hepatitis A virus transmission by blood products in the United States. Transfusion Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980006-X

7 January 2021

Has hepatitis A virus been transmitted by clotting factor concentrates among hemophiliacs in the United States?

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980006-X

7 January 2021

A study of hepatitis A virus infection among hemophilia patients in New York City

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980006-X

7 January 2021

FDA perspective on and response to the risk of hepatitis A from blood products

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980006-X

7 January 2021

Transmission of human parvovirus B19 by coagulation factor concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980006-X

7 January 2021

Transfusion-transmitted human parvovirus B19 infection in a thalassemic patient

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980006-X

7 January 2021

Human parvovirus B19 infection in hemophiliacs first infused with two high‐purity, virally attenuated factor Vlll concentrates

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980006-X

7 January 2021

Virus-inactivated factor VIII concentrate prevents postoperative bleeding in a patient with von Willebrand's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980006-X

7 January 2021

Hepatitis C virus infection in hypogammaglobulinemic patients receiving long-term replacement therapy with intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980006-X

7 January 2021

Tolerability and kinetics of a solvent-detergent-treated intravenous immunoglobulin preparation in hypogammaglobulinaemia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980006-X

7 January 2021

Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980006-X

7 January 2021

Unusually large plasma factor VIII:von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS0887-7963%2896%2980006-X

7 January 2021

10.1016/S0887-7963(96)80006-X

Identifiers

DOI

1 reference

28 September 2017

1 reference

PubMed ID

8899959